Key result
Between 2012 and 2018, metformin remained the most prescribed antidiabetic drug for patients with heart failure and diabetes, with increasing use of DPP-4 and SGLT-2 inhibitors and decreasing use of sulfonylureas.
Why the study?
There was a need to analyze contemporary antidiabetic pharmacotherapy patterns in patients with diabetes mellitus and heart failure at a national level in the Czech Republic.
Observational (n=117,265)
Answers are grounded in this paper and cite their sources.
This national registry analysis demonstrates an increasing prevalence of concurrent heart failure and diabetes, with a shift in prescribing patterns towards newer agents like DPP-4 and SGLT-2 inhibitors.
AIM: Retrospective national sub-analysis of antidiabetic pharmacotherapy in patients with diabetes mellitus (DM) and heart failure (HF) based on data reported to the National Register of Paid Health Services in the Czech Republic between 2012-2018. METHODOLOGY AND RESULTS: In 2012, there were 75,022 patients with HF and DM (i.e. 42.5% of patients with HF), 6 years later 117,265 (i.e. 41.0% of HF patients in 2018). The most represented antidiabetic drug was metformin (45.6%). Of the insulins and analogues, glargine showed the largest positive trend (5.8% 2012; 14.8% 2018). Empagliflozin was the most prescribed SGLT-2 inhibitor (1.8% in 2018). A decrease in prescribing was observed for saxagliptin (0.5% 2012; 0.1% 2018) and for sulfonylurea derivates - gliclazide (13.0% 2012; 10.3% in 2018) and glimepiride (12.9% 2012; 9.0% 2018). Linagliptin was the most prescribed dipeptidyl peptidase inhibitor (0.7% 2012; 6.8% 2018). CONCLUSION: In the Czech Republic, between 2012 and 2008, there was an increase in prevalence of patients with heart failure and concomitant diabetes mellitus, their proportion being similar. In correspondence with other registries, metformin was used mostly. A positive trend was observed in prescription of DDP-4 and SGLT-2 inhibitors, while there was a significant decrease in patients taking sulfonylureas.
No takes yet. Share an insight, caveat, or question.
Vícha et al. (2021) conducted an observational in Heart failure and diabetes mellitus (n=117,265). Antidiabetic pharmacotherapy was evaluated on Prevalence and trends of antidiabetic drug prescriptions. Between 2012 and 2018, metformin remained the most prescribed antidiabetic drug for patients with heart failure and diabetes, with increasing use of DPP-4 and SGLT-2 inhibitors and decreasing use of sulfonylureas.
Synapse has enriched 10 related papers. Consider them for comparative context: